Empirical Antifungal Therapy — New Options, New Tradeoffs

Publisher Website
Google Scholar
Abstract
The risk of fungal infections increases greatly in patients with profound and protracted neutropenia. Because of the insensitivity of diagnostic methods and the poor outcomes associated with established infections, empirical antifungal therapy is used for patients with neutropenia who have persistent fever despite the administration of antibacterial agents. Although conventional amphotericin B has been considered the optimal first-line agent, its status as the preferred treatment has recently been challenged by the results of trials comparing it with antifungal triazoles and lipid formulations of amphotericin B (Table 1).A report in this issue of the Journal further advances our knowledge about . . .

This publication has 10 references indexed in Scilit: